Company intelligence / Profile preview

Novostia

Lausanne, Vaud, Switzerlandnovostia.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Novostia has developed a new generation of artificial heart valves designed to address major unmet needs in the treatment of heart valve diseases. Their Triflo Valve is engineered for low thrombogenicity, lifelong durability, and minimal acoustic signature. The technology has demonstrated promising results in both in-vitro and in-vivo studies. The company is currently preparing for its first-in-human clinical trials with strong support from key opinion leaders.

Therapeutic areas: Cardiovascular
Modalities: DeviceArtificial heart valve (medical device)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

TRIFLO Heart Valve

Phase 1

Indications: Heart valve disease

Partnerships

European Union’s Horizon 2020 research programcollaborations with academic laboratories and world leaders in fluid mechanics and biomaterials

Beyond the preview

Go deeper on Novostia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novostia.

Explore the full profile